CAR-T细胞治疗淋巴瘤——我们仍然在路上

韩为东; 张亚晶

doi:10.13201/j.issn.1004-2806.2022.09.002

CAR-T细胞治疗淋巴瘤——我们仍然在路上

韩为东^1, ,,
张亚晶¹

- 解放军总医院生物治疗科(北京，100853)
基金项目:
国家自然科学基金(No：81830002、31870873、31991171、82150108、32070951)

详细信息

作者简介:
韩为东，临床医学博士，教授，临床肿瘤学博士研究生导师，国家百千万人才，首都科技创新领军人才，国务院政府特贴专家，原总后勤部科技新星，解放军总医院生物治疗科主任。主要从事肿瘤治疗抵抗机制与肿瘤免疫治疗的临床研究。先后承担科技部重大专项1项，973课题2项，863项目3项，国家自然基金重大项目1项，重点项目2项，专项原创1项，面上项目7项，北京市生物技术前沿项目1项，获得企业投资3项，4项临床治疗技术企业转让。国家发明专利20余项。主编专著3部。以第一作者或通讯作者在JCO、Cell Res、Blood、Nat Cancer、CCR、NAR、JNCI、STTT、Nat Comm、JHO、Leukemia等学术期刊发表SCI论文170余篇，累计影响因子1 100余分，H指数45。参与、获得省部级二等奖以上4项。2015年成立了中国研究型医院生物治疗学专业委员会(二级学会)，并担任首届主任委员

通讯作者: 韩为东，E-mail：hanwdrsw@163.com

中图分类号: R733.4

收稿日期: 2022-03-24

刊出日期: 2022-09-01

CAR-T cell therapy for lymphoma——still on the way

HAN Weidong^1, ,,
ZHANG Yajing¹

More Information

Corresponding author: HAN Weidong, E-mail: hanwdrsw@163.com

Received Date: 24 March 2022

Publish Date: 01 September 2022

摘要

- 嵌合抗原受体T细胞治疗 /
- 淋巴瘤
- chimeric antigen receptor T cells therapy /
- lymphoma

HTML全文

参考文献(33)

[1]	Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas(JULIET): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2021, 22(10): 1403-1415. doi: 10.1016/S1470-2045(21)00375-2
[2]	Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396(10254): 839-852. doi: 10.1016/S0140-6736(20)31366-0
[3]	Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1): 31-42. doi: 10.1016/S1470-2045(18)30864-7
[4]	Cappell KM, Sherry RM, Yang JC, et al. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy[J]. J Clin Oncol, 2020, 38(32): 3805-3815. doi: 10.1200/JCO.20.01467
[5]	Charles Herbaux. Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a"Real-Life"Study from the Descar-T Registry and Lysa Group[C]. Presented at: 63rd ASH Annual Meeting and Exposition. Oral 743.
[6]	Emmanuel Bachy. Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry[C]. Presented at: 63rd ASH Annual Meeting and Exposition. Oral 92A.
[7]	Yucai Wang. Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium[C]. Presented at: 63rd ASH Annual Meeting and Exposition. Oral 744.
[8]	Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium[J]. J Clin Oncol, 2020, 38(27): 3119-3128. doi: 10.1200/JCO.19.02104
[9]	Zhang T, Cao L, Xie J, et al. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis[J]. Oncotarget, 2015, 6(32): 33961-33971. doi: 10.18632/oncotarget.5582
[10]	Neelapu SS. CAR-T efficacy: is conditioning the key?[J]. Blood, 2019, 133(17): 1799-1800. doi: 10.1182/blood-2019-03-900928
[11]	Lyu C, Cui R, Wang J, et al. Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk[J]. Front Oncol, 2021, 11: 706087. doi: 10.3389/fonc.2021.706087
[12]	Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells[J]. Sci Transl Med, 2016, 8(355): 355ra116.
[13]	Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy[J]. Blood, 2019, 133(15): 1652-1663. doi: 10.1182/blood-2018-11-883710
[14]	National Cancer Institute.Common terminology criteria for adverse events(CTCAE).Version 5.0[EB/OL]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.Accessed July 20, 2018.
[15]	Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. doi: 10.1016/j.bbmt.2018.12.758
[16]	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi: 10.1038/nrclinonc.2017.148
[17]	Park JH, Riviere I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2018, 378(5): 449-459. doi: 10.1056/NEJMoa1709919
[18]	Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel[J]. J Hematol Oncol, 2018, 11(1): 35. doi: 10.1186/s13045-018-0571-y
[19]	Cao Y, Xiao Y, Wang N, et al. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas[J]. Transplant Cell Ther, 2021, 27(11): 910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012
[20]	Zhang Y, Wang Y, Liu Y, et al. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial[J]. Leukemia, 2022, 36(1): 189-196. doi: 10.1038/s41375-021-01345-8
[21]	Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma[J]. Signal Transduct Target Ther, 2020, 5(1): 134. doi: 10.1038/s41392-020-00256-x
[22]	韩为东, 梁爱斌, 钱文斌. CAR T细胞治疗NHL毒副作用临床管理路径指导原则[M]. 北京: 清华大学出版社, 2021: 17-22.
[23]	中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会. 靶向B细胞和浆细胞的CAR-T细胞治疗中防治乙型肝炎病毒再激活的中国专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(6): 441-446.
[24]	Li X, Dai H, Li X, et al. Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done?[J]. Cell Mol Immunol, 2022, 19(1): 122-124. doi: 10.1038/s41423-021-00789-3
[25]	Yan X, Chen D, Wang Y, et al. Identification of NOXA as a pivotal regulator of resistance to CAR T cell therapy in B-cell malignancies[J]. Signal Transduct Target Ther, 2022, 7(1): 98. doi: 10.1038/s41392-022-00915-1
[26]	Lei X, Ou Z, Yang Z, et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors[J]. Clin Cancer Res, 2021, 27(13): 3757-3771. doi: 10.1158/1078-0432.CCR-20-2487
[27]	Wang C, Shi F, Liu Y, et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy[J]. J Hematol Oncol, 2021, 14(1): 106. doi: 10.1186/s13045-021-01120-3
[28]	Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes[J]. J Clin Invest, 2021, 131(2): e142030. doi: 10.1172/JCI142030
[29]	Wang Y, Tong C, Dai H, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming[J]. Nat Commun, 2021, 12(1): 409. doi: 10.1038/s41467-020-20696-x
[30]	Qin JS, Johnstone TG, Baturevych A, et al. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib[J]. J Immunother, 2020, 43(4): 107-120. doi: 10.1097/CJI.0000000000000307
[31]	Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia[J]. Blood, 2016, 127(9): 1117-1127. doi: 10.1182/blood-2015-11-679134
[32]	Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure[J]. Blood, 2020, 135(19): 1650-1660. doi: 10.1182/blood.2019002936
[33]	Wu J, Meng F, Cao Y, et al. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma[J]. Blood Cancer J, 2021, 11(7): 131. doi: 10.1038/s41408-021-00523-2